13F filing recap · Q1 2025
What did Bill & Melinda Gates Foundation Trust buy in Q1 2025?
Reported stock-position changes between this filing and the previous one.
Stock value
$41.81B
Positions
25
Estimated turnover
3.4%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Bill & Melinda Gates Foundation Trust opened a new position in West Pharmaceutical Services and trimmed its Berkshire Hathaway stake.